Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Curcumin dually inhibits both mTOR and NF-κB pathways through a crossed PI3K/Akt/IKK signaling axis in adenoid cystic carcinoma

Zhi-Jun Sun, Gang Chen, Wei Zhang, Xiang Hu, Yang Liu, Qian Zhou, Ling-Xin Zhu and Yi-Fang Zhao
Molecular Pharmacology October 19, 2010, mol.110.066910; DOI: https://doi.org/10.1124/mol.110.066910
Zhi-Jun Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qian Zhou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling-Xin Zhu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Fang Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Adenoid cystic carcinoma (ACC) is a highly malignant tumor that is generally unresponsive or only weakly responsive to the currently available antineoplastic agents. Thus novel therapeutic strategies and agents are urgently needed to treat this aggressive neoplasm. Curcumin, a component of turmeric (Curcuma longa), has been shown to have a diversity of anti-tumor activities. We show here that curcumin is a potent inhibitor of ACC progression in vitro and in vivo. Curcumin concentration-dependently inhibited the growth of ACC cells via induction of apoptosis. The ability of ACC cells to migrate/invade and induce angiogenesis was also significantly attenuated by curcumin, accompanied by the down-regulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 and -9. Moreover, our data also demonstrated that the inhibitory effects of curcumin on ACC cells were due to its dual-inhibition of both mammalian target of rapamycin (mTOR) and nuclear factor-κB (NF-κB) pathways through a crossed PI3K/Akt/IKK signaling axis. Most importantly, curcumin effectively prevented the in vivo growth and angiogenesis of ACC xenografts in nude mice, as revealed by the induction of cell apoptosis and reduction of microvessel density (MVD) in tumor tissues. Additionally, we further assessed the nature activation status of both mTOR and NF-κB pathways in ACC tissues, and confirmed the concurrent high activation of these two pathways in ACC for the first time. Taken together, our findings suggest that further clinical investigation is warranted to apply curcumin as a novel chemotherapeutic regimen for ACC due to its dual-suppression of both mTOR and NF-κB pathways.

  • NFkappaB
  • Signaling network analyses
  • Apoptosis
  • Mechanisms of cell killing/apoptosis
  • Angiogenesis
  • Received June 15, 2010.
  • Revision received October 19, 2010.
  • Accepted October 19, 2010.
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 103 (6)
Molecular Pharmacology
Vol. 103, Issue 6
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Curcumin dually inhibits both mTOR and NF-κB pathways through a crossed PI3K/Akt/IKK signaling axis in adenoid cystic carcinoma
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Curcumin dually inhibits both mTOR and NF-κB pathways through a crossed PI3K/Akt/IKK signaling axis in adenoid cystic carcinoma

Zhi-Jun Sun, Gang Chen, Wei Zhang, Xiang Hu, Yang Liu, Qian Zhou, Ling-Xin Zhu and Yi-Fang Zhao
Molecular Pharmacology October 19, 2010, mol.110.066910; DOI: https://doi.org/10.1124/mol.110.066910

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Curcumin dually inhibits both mTOR and NF-κB pathways through a crossed PI3K/Akt/IKK signaling axis in adenoid cystic carcinoma

Zhi-Jun Sun, Gang Chen, Wei Zhang, Xiang Hu, Yang Liu, Qian Zhou, Ling-Xin Zhu and Yi-Fang Zhao
Molecular Pharmacology October 19, 2010, mol.110.066910; DOI: https://doi.org/10.1124/mol.110.066910
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
  • Allosteric Modulation of Metabotropic Glutamate Receptor 1
  • Mechanism of Selective Action of Paraherquamide A
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics